UNSPSC 51182027: Flutamide

This classification denotes an aromatic compound and anti-androgen with the molecular formula C11H11F3N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 76W6J0943E, chemically known as propanamide, 2-methyl-n-(4-nitro-3-(trifluoromethyl)phenyl)- but generally known as flutamide, which bears US NIH Compound Identifier 3397. European Medicines Agency schedules Flutamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07756MIG.

UNSPSC 51182027 Flutamide is a Commodity code covering the procurement of this specific generic pharmaceutical ingredient and finished-dose products by state and local health systems, correctional facilities, and cooperative purchasing alliances. State and local governments acquire flutamide primarily through multistate pharmaceutical cooperative purchasing agreements that consolidate demand across participating jurisdictions and facilities to achieve volume pricing. The drug is procured as part of broader generic and branded pharmaceutical sourcing initiatives rather than through standalone flutamide-specific solicitations. Issuing bodies include state departments of administration overseeing health facility procurement, state prison systems, county jail systems, and state Medicaid agencies, coordinated through cooperative purchasing vehicles that pool purchasing power across multiple states and local government entities.

Activity under this code concentrates in multistate cooperative purchasing frameworks, most notably the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which is administered by the Minnesota Department of Administration's Office of State Procurement and spans participating states including Oregon. MMCAP issued a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with a response deadline of March 26, 2026. The procurement requires manufacturers to supply flutamide and other identified pharmaceuticals with detailed pricing in formats including flat price, net price structures, or WAC-minus models, through three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Awards are expected to become effective July 1, 2026, with a two-year initial contract term and optional extensions at the alliance's discretion. Vendors must hold $5 million in commercial general liability coverage and comply with cGMP certification and Drug Supply Chain Security Act requirements.